The protein STING plays a crucial role in enabling the immune system to mount a first defense against pathogen infection and tumor growth. It is still unknown how STING exerts its potent anti-cancer effects, and in particular how STING interprets different stimuli and controls distinct downstream signaling responses. Dr. Carina de Oliveira Mann will address this fundamental question by defining the mechanism of differential STING-induced signaling, and determining how synergy between alternative STING responses affects antiviral and antitumor immunity. Dr. de Oliveira Mann’s research aims to identify the components of STING that are responsible for these activities, and potentially discover new avenues through which STING can be used to enhance immune responses against cancer.
Dana-Farber Cancer Institute | All Cancers | 2017 | Philip Kranzusch, Ph.D.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
Rare and ultra-rare cancers affect around 20,000 people in the United States alone, according to Foundation Medicine, Inc. Immunotherapy research in some of the more common cancers and the identification of biomarkers that can predict patient responses is opening this new approach to cancer treatment up to patients whose cancers currently receive little direct attention.
Cancer is not “one-size-fits-all” and neither are its treatments, especially when it comes to immunotherapy. Learn how CRI is helping more people overcome cancer.